Search

Your search keyword '"Walsh, R. Matthew"' showing total 456 results
Start Over Author "Walsh, R. Matthew" Publication Type Academic Journals
456 results on '"Walsh, R. Matthew"'

5. Physiologic tension of the abdominal wall

Author

Miller, Benjamin T., Ellis, Ryan C., Walsh, R. Matthew, Joyce, Daniel, Simon, Robert, Almassi, Nima, Lee, Byron, DeBernardo, Robert, Steele, Scott, Haywood, Samuel, Beffa, Lindsey, Tu, Chao, and Rosen, Michael J.

Published
2023
Full Text
View/download PDF

24. Tumor Mutational Burden From Circulating Tumor DNA Predicts Recurrence of Hepatocellular Carcinoma After Resection: An Emerging Biomarker for Surveillance.

Author

Wehrle, Chase J., Hong, Hanna, Kamath, Suneel, Schlegel, Andrea, Masato Fujiki, Koji Hashimoto, Choon Hyuck Kwon, David, Miller, Charles, Walsh, R. Matthew, and Aucejo, Federico

Abstract

Objective: Describe the utility of circulating tumor DNA in the postoperative surveillance of hepatocellular carcinoma (HCC). Background: Current biomarkers for HCC like alpha-fetoprotein (AFP) are lacking. Circulating tumor DNA (ctDNA) has shown promise in colorectal and lung cancers, but its utility in HCC remains relatively unknown. Methods: Patients with HCC undergoing curative-intent resection from November 1, 2020, to July 1, 2023, received ctDNA testing using the Guardant360 platform. Tumor mutational burden (TMB) is calculated as the number of somatic mutations-per-megabase of genomic material identified. Results: Forty-seven patients had postoperative ctDNA testing. The mean follow-up was 27 months, and the maximum was 43.2 months. Twelve patients (26%) experienced recurrence. Most (n=41/47, 87.2%) had identifiable ctDNA postoperatively; 55.3% (n=26) were TMB-not detected versus 45.7% (n= 21) TMBdetectable. Postoperative identifiable ctDNA was not associated with RFS (P=0.518). Detectable TMB was associated with reduced RFS (6.9 vs 14.7 mo, P=0.049). There was a higher rate of recurrence in patients with TMB (n=9/21, 42.9%, vs n= 3/26, 11.5%, P=0.02). Area under the curve for TMB-prediction of recurrence was 0.752 versus 0.550 for AFP. ROC analysis established a TMB cutoff of 4.8mut/mB for predicting post-operative recurrence (P=0.002) and RFS (P=0.025). AFP was not correlated with RFS using the lab-normal cutoff (< 11 ng/mL, P=0.682) or the cutoff established by ROC analysis (=4.6 ng/mL, P=0.494). TMB-high was associated with poorer RFS on cox-regression analysis (hazard ratio=5.386, 95% CI: 1.109-26.160, P=0.037), while microvascular invasion (P= 0.853) and AFP (P=0.439) were not. Conclusions: Identifiable TMB on postoperative ctDNA predicts HCC recurrence and outperformed AFP in this cohort. Perioperative ctDNA may be a useful surveillance tool following curativeintent hepatectomy. Larger-scale studies are needed to confirm this utility and investigate additional applications in HCC patients, including the potential for prophylactic treatment in patients with residual TMB after resection. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

26. Advances in the management of pancreatic cystic neoplasms

Author

Walsh, R. Matthew, Perlmutter, Breanna C., Adsay, Volkan, Reid, Michelle D., Baker, Mark E., Stevens, Tyler, Hue, Jonathan J., Hardacre, Jeffrey M., Shen, Gong-Qing, Simon, Robert, Aleassa, Essa M., Augustin, Toms, Eckhoff, Austin, Allen, Peter J., and Goh, Brian K.P.

Published
2021
Full Text
View/download PDF

31. Emerging and Clinically Accepted Biomarkers for Hepatocellular Carcinoma.

Author

Fares, Sami, Wehrle, Chase J., Hong, Hanna, Sun, Keyue, Jiao, Chunbao, Zhang, Mingyi, Gross, Abby, Allkushi, Erlind, Uysal, Melis, Kamath, Suneel, Ma, Wen Wee, Modaresi Esfeh, Jamak, Linganna, Maureen Whitsett, Khalil, Mazhar, Pita, Alejandro, Kim, Jaekeun, Walsh, R. Matthew, Miller, Charles, Hashimoto, Koji, and Schlegel, Andrea

Subjects
EDUCATION of physicians, PUBLIC health surveillance, BLOOD testing, GENOMICS, GLYCOSYLATION, TUMOR markers, METASTASIS, NUCLEIC acids, EXTRACELLULAR space, METABOLOMICS, HEPATOCELLULAR carcinoma, SENSITIVITY & specificity (Statistics), LIVER transplantation
Abstract

Simple Summary: This review article serves to update physicians on what biomarker tests are available for the surveillance and follow up of hepatocellular carcinoma. Our goal is to provide an update on newly arising tests and their diagnostic accuracy when compared to the standard protocol. Findings from this article hope to promote further investigation into high utility tests and continue the pursuit of clinical utility for emerging biomarkers such as circulating tumor DNA. Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death and the sixth most diagnosed malignancy worldwide. Serum alpha-fetoprotein (AFP) is the traditional, ubiquitous biomarker for HCC. However, there has been an increasing call for the use of multiple biomarkers to optimize care for these patients. AFP, AFP-L3, and prothrombin induced by vitamin K absence II (DCP) have described clinical utility for HCC, but unfortunately, they also have well established and significant limitations. Circulating tumor DNA (ctDNA), genomic glycosylation, and even totally non-invasive salivary metabolomics and/or micro-RNAS demonstrate great promise for early detection and long-term surveillance, but still require large-scale prospective validation to definitively validate their clinical validity. This review aims to provide an update on clinically available and emerging biomarkers for HCC, focusing on their respective clinical strengths and weaknesses. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

39. Circulating Tumor DNA Profiling in Liver Transplant for Hepatocellular Carcinoma, Cholangiocarcinoma, and Colorectal Liver Metastases: A Programmatic Proof of Concept.

Author

Hong, Hanna, Wehrle, Chase J., Zhang, Mingyi, Fares, Sami, Stitzel, Henry, Garib, David, Estfan, Bassam, Kamath, Suneel, Krishnamurthi, Smitha, Ma, Wen Wee, Kuzmanovic, Teodora, Azzato, Elizabeth, Yilmaz, Emrullah, Modaresi Esfeh, Jamak, Linganna, Maureen Whitsett, Khalil, Mazhar, Pita, Alejandro, Schlegel, Andrea, Kim, Jaekeun, and Walsh, R. Matthew

Subjects
DNA analysis, LIVER tumors, GENOMICS, CHOLANGIOCARCINOMA, COLORECTAL cancer, BODY fluid examination, DESCRIPTIVE statistics, METASTASIS, LONGITUDINAL method, NUCLEIC acids, GENE expression profiling, EXTRACELLULAR space, GENETIC mutation, DATA analysis software, HEPATOCELLULAR carcinoma, LIVER transplantation, BIOMARKERS, BLOOD
Abstract

Simple Summary: Circulating tumor DNA (ctDNA) is emerging as a diagnostic and surveillance tool in cancer and recurrence. The recurrence rates after liver transplant for cancer are significant, highlighting the need for early detection and treatment. We report a cohort of patients who underwent liver transplant for hepatocellular carcinoma, cholangiocarcinoma, or colorectal cancer liver metastasis and received ctDNA testing pre- and/or post-transplant. We aim to show how ctDNA testing can be incorporated into pre-transplant work-up and post-transplant surveillance and discuss the benefits of this testing modality in the identification of genetic targets and surveillance of recurrence. Introduction: Circulating tumor DNA (ctDNA) is emerging as a promising, non-invasive diagnostic and surveillance biomarker in solid organ malignancy. However, its utility before and after liver transplant (LT) for patients with primary and secondary liver cancers is still underexplored. Methods: Patients undergoing LT for hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA), and colorectal liver metastases (CRLM) with ctDNA testing were included. CtDNA testing was conducted pre-transplant, post-transplant, or both (sequential) from 11/2019 to 09/2023 using Guardant360, Guardant Reveal, and Guardant360 CDx. Results: 21 patients with HCC (n = 9, 43%), CRLM (n = 8, 38%), CCA (n = 3, 14%), and mixed HCC/CCA (n = 1, 5%) were included in the study. The median follow-up time was 15 months (range: 1–124). The median time from pre-operative testing to surgery was 3 months (IQR: 1–4; range: 0–5), and from surgery to post-operative testing, it was 9 months (IQR: 2–22; range: 0.4–112). A total of 13 (62%) patients had pre-transplant testing, with 8 (62%) having ctDNA detected (ctDNA+) and 5 (32%) not having ctDNA detected (ctDNA-). A total of 18 (86%) patients had post-transplant testing, 11 (61%) of whom were ctDNA+ and 7 (33%) of whom were ctDNA-. The absolute recurrence rates were 50% (n = 5) in those who were ctDNA+ vs. 25% (n = 1) in those who were ctDNA- in the post-transplant setting, though this difference was not statistically significant (p = 0.367). Six (29%) patients (HCC = 3, CCA = 1, CRLM = 2) experienced recurrence with a median recurrence-free survival of 14 (IQR: 6–40) months. Four of these patients had positive post-transplant ctDNA collected following diagnosis of recurrence, while one patient had positive post-transplant ctDNA collected preceding recurrence. A total of 10 (48%) patients had sequential ctDNA testing, of whom n = 5 (50%) achieved ctDNA clearance (+/−). The remainder were ctDNA+/+ (n = 3, 30%), ctDNA−/− (n = 1, 10%), and ctDNA−/+ (n = 1, 11%). Three (30%) patients showed the acquisition of new genomic alterations following transplant, all without recurrence. Overall, the median tumor mutation burden (TMB) decreased from 1.23 mut/Mb pre-transplant to 0.00 mut/Mb post-transplant. Conclusions: Patients with ctDNA positivity experienced recurrence at a higher rate than the ctDNA- patients, indicating the potential role of ctDNA in predicting recurrence after curative-intent transplant. Based on sequential testing, LT has the potential to clear ctDNA, demonstrating the capability of LT in the treatment of systemic disease. Transplant providers should be aware of the potential of donor-derived cell-free DNA and improved approaches are necessary to address such concerns. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

45. Minimally invasive pancreatoduodenectomy

Author

Asbun, Horacio J., Barkun, Jeffrey, Besselink, Marc GH., Boggi, Ugo, Conlon, Kevin CP., Han, Ho-Seong, Hansen, Paul D., Kendrick, Michael L., Kooby, David A., Montagnini, Andre L., Palanivelu, C., Røsok, Bård I., Shrikhande, Shailesh V., Wakabayashi, Go, Zeh, Herbert, Vollmer, Charles M., van Hilst, Jony, de Rooij, Thijs, Walsh, R. Matthew, Zeh, Herbert J., Hughes, Steven J., and Nakamura, Yoshiharu

Published
2017
Full Text
View/download PDF

47. Circulating Tumor DNA in Colorectal Cancer Liver Metastasis: Analysis of Patients Receiving Liver Resection and Transplant.

Author

Wehrle, Chase J., Raj, Roma, Aykun, Nihal, Orabi, Danny, Stackhouse, Kathryn, Chang, Jenny, Estfan, Bassam, Kamath, Suneel, Krishnamurthi, Smitha, Walsh, R. Matthew, Kwon, David Choon Hyuck, and Aucejo, Federico

Subjects
CIRCULATING tumor DNA, COLORECTAL liver metastasis, IRINOTECAN, LIVER analysis, LIVER transplantation, SOMATIC mutation, COLON tumors
Abstract

PURPOSE: Liver metastases occur in about 50% of colorectal cancer cases and drive patient outcomes. Circulating tumor DNA (ctDNA) is emerging as a diagnostic, surveillance, and tumor mutational information tool. METHODS: Patients with colorectal cancer liver metastasis (CCLM) seen in a multidisciplinary liver tumor clinic from January to August 2022 received ctDNA testing on each visit. ctDNA was obtained using the Guardant360 platform. Tumor mutational burden (TMB) is defined as the number of identified mutations per megabase of genome analyzed. RESULTS: Fifty-two patients had available ctDNA, with 34 (65%) tested preoperatively and 18 (35%) postoperatively; nine patients had sequential pre- and postoperative testing. The median time to test result was 12 days (IQR, 10-13.5). There were a greater number of somatic mutations identified preoperatively (n = 29 v n = 11) and a greater genomic heterogeneity (P =.0069). The mean TMB score was 12.77 in those without pathologic response to cytotoxic therapy and 6.0 in those with pathologic response (P =.10). All nine patients with sequential testing were positive preoperatively, compared with just three (33.3%) postoperatively (P =.0090). Positive postoperative ctDNA was associated with the increased likelihood of disease recurrence after resection (57%) versus negative ctDNA (0%, P =.0419). CONCLUSION: Routine ctDNA screening in patients with CCLM is logistically feasible. Liver resection and/or transplant may be associated with clearance of detectable ctDNA and a reduction in TMB or genomic heterogeneity. Persistence of ctDNA alterations postresection appears predictive of disease recurrence. Further studies are necessary to confirm these findings, and longitudinal ctDNA testing is needed to monitor changing tumor biology. Detectable ctDNA after transplant and/or resection for colorectal liver metastasis can predict recurrence. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

48. The Miami International Evidence-based Guidelines on Minimally Invasive Pancreas Resection

Author

Asbun, Horacio J., Moekotte, Alma L., Vissers, Frederique L., Kunzler, Filipe, Cipriani, Federica, Alseidi, Adnan, D’Angelica, Michael I., Balduzzi, Alberto, Bassi, Claudio, Björnsson, Bergthor, Boggi, Ugo, Callery, Mark P., Del Chiaro, Marco, Coimbra, Felipe J., Conrad, Claudius, Cook, Andrew, Coppola, Alessandro, Dervenis, Christos, Dokmak, Safi, Edil, Barish H., Edwin, Bjørn, Giulianotti, Pier C., Han, Ho-Seong, Hansen, Paul D., van der Heijde, Nicky, van Hilst, Jony, Hester, Caitlin A., Hogg, Melissa E., Jarufe, Nicolas, Jeyarajah, D. Rohan, Keck, Tobias, Kim, Song Cheol, Khatkov, Igor E., Kokudo, Norihiro, Kooby, David A., Korrel, Maarten, de Leon, Francisco J., Lluis, Nuria, Lof, Sanne, Machado, Marcel A., Demartines, Nicolas, Martinie, John B., Merchant, Nipun B., Molenaar, I. Quintus, Moravek, Cassadie, Mou, Yi-Ping, Nakamura, Masafumi, Nealon, William H., Palanivelu, Chinnusamy, Pessaux, Patrick, Pitt, Henry A., Polanco, Patricio M., Primrose, John N., Rawashdeh, Arab, Sanford, Dominic E., Senthilnathan, Palanisamy, Shrikhande, Shailesh V., Stauffer, John A., Takaori, Kyoichi, Talamonti, Mark S., Tang, Chung N., Vollmer, Charles M., Wakabayashi, Go, Walsh, R. Matthew, Wang, Shin-E, Zinner, Michael J., Wolfgang, Christopher L., Zureikat, Amer H., Zwart, Maurice J., Conlon, Kevin C., Kendrick, Michael L., Zeh, Herbert J., Hilal, Mohammad Abu, and Besselink, Marc G.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results